Clinical Research Support | Departments | Trials | Frequently Asked Questions | Request Trial Information
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Ochsner accepts all major insurances.
Ochsner is a 501(c)3 not-for-profit organization, founded on providing the best patient care, research, and education.
We are one of the country’s largest non-university based academic medical centers.